USFDA approves Strides Arcolab 's Benzonatate capsules

Published On 2015-08-01 09:58 GMT   |   Update On 2015-08-01 09:58 GMT
Advertisement
NEW DELHI: Drug firm Strides Arcolab has received approval from the US health regulator for its Benzonatate softgel capsules used for treating cough caused by cold, and other breathing problems such as pneumonia and asthma.

The product will be launched immediately in the US market, Strides Arcolab said in a filing to BSE.

The company has received approval from the United States Food and Drug Administration (USFDA) for Benzonatate softgel capsules in the strengths of 100mg and 200 mg, it added.

"According to IMS data, the US market for Benzonatate is approximately USD 41 million," Strides Arcolab said.

The product will be manufactured at the company's oral dosage facility at Bengaluru and marketed by the company in the US, it added.

Strides Arcolab is a bang lore based pharmaceutical company manufacturing pharmaceutical products, OTC drugs and nutraceuticals
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News